Neuronetics

Clinicians and treatment centers continue adopting Neuronetics’ TMS platform because it addresses patients who need a non-drug depression treatment pathway, and that adoption keeps converting into procedure-driven revenue rather than a one-time hardware spike. If adoption remains durable, the larger installed/provider base can support recurring revenue; if referrals move elsewhere, the 2025 step-up will not compound.

Neuronetics must preserve enough device-like pricing power and recurring treatment economics so growth is not merely bought by shifting into lower-margin clinic or services revenue. If gross profit dollars scale with revenue, the business can fund commercialization; if mix or discounting structurally compresses margin, revenue growth may destroy value.

The larger commercial base must allow sales, service, clinical-support, and corporate infrastructure to scale more efficiently, so incremental revenue reduces GAAP operating losses rather than requiring proportional spending. Operating leverage is the bridge from a promising therapy platform to equity value; without it, growth remains dependent on outside capital.

Neuronetics must move toward self-funding before balance-sheet constraints force dilutive equity issuance or expensive debt that captures the upside from operating progress. For common shareholders, survival is not enough; if the turnaround is financed with heavy dilution, per-share value may not follow business improvement.